Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Open access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Revisiting surrogacy of pathological complete response for long-term survival in triple-negative breast cancer.JNCI cancer spectrum · 2025Pooled it
- Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2021Pooled it
- Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer.Breast cancer research and treatment · 2025Trial
- Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.European radiology · 2022Trial
- Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.Scientific reports · 2021Trial
- Current and future therapies for triple-negative breast cancer.Journal of hematology & oncology · 2026Review
- Computation-driven discovery of novel chromone derivatives for the treatment of triple-negative breast cancerActa pharmaceutica Sinica. B · 2026Article
- Beyond Molecular Classification in Metastatic Triple-Negative Breast Cancer: Toward Subtype-Guided Precision Oncology.International journal of molecular sciences · 2026Review
- Combined Treatment with Shuyu Pills and Everolimus Suppresses Triple-Negative Breast Cancer Growth via the PI3K/AKT/mTOR Pathway.Breast cancer (Dove Medical Press) · 2026Article
- Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer.ACS nano · 2025Article
- Review
- Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations.Breast cancer research : BCR · 2025Article
- Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine.Cancer research communications · 2025Article
- Concurrent Neoadjuvant Chemotherapy and Radiation in Locally Advanced Breast Cancer: Impact on Locoregional Recurrence Rates.Current oncology (Toronto, Ont.) · 2025Article
- Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment.Metabolites · 2024Review
- Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound.ACS pharmacology & translational science · 2024Article
- Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.Cancer letters · 2024Article
- Overexpression of KLHL22 correlates with poor prognosis in patients with triple-negative breast cancer.Translational cancer research · 2024Article
- Mapping cancer biology in space: applications and perspectives on spatial omics for oncology.Molecular cancer · 2024Review
- SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus.Cancer biology & therapy · 2023Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 2 institutions in 1 country.
Bojana JovanovićDana-Farber Cancer Institute, Boston, Massachusetts.
Ingrid A MayerVanderbilt-Ingram Cancer Center, Nashville, Tennessee. ingrid.mayer@vanderbilt.edu jennifer.pietenpol@vanderbilt.edu.
Erica L MayerDana-Farber Cancer Institute, Boston, Massachusetts.
Vandana G AbramsonVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Melinda E SandersVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
M Gabriela KubaVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Monica V EstradaVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
J Scott BeelerVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Timothy M ShaverVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Kimberly C JohnsonVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Violeta SanchezVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Jennifer M RosenbluthDana-Farber Cancer Institute, Boston, Massachusetts.
Patrick M DillonUniversity of Virginia Health Sciences Center, Charlottesville, Virginia.
Andres Forero-TorresUniversity of Alabama, Birmingham, Alabama.
Jenny C ChangMethodist Hospital Research Institute, Houston, Texas.
Ingrid M MeszoelyVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Ana M GrauVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Brian D LehmannVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Yu ShyrVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Quanhu ShengVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Sheau-Chiann ChenVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Carlos L ArteagaVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Jennifer A PietenpolVanderbilt-Ingram Cancer Center, Nashville, Tennessee. ingrid.mayer@vanderbilt.edu jennifer.pietenpol@vanderbilt.edu.
Dana-Farber Cancer Institute · USMassachusetts General Hospital · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MP53 SIGNALING AND CELLULAR RESPONSE AFTER STRESSR01CA070856 · NCI · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 1997 to 2010
$3.8Mp63 Signaling in Epithelial Cell Growth and CancerR01CA105436 · NCI · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2004 to 2014
$3.1MTargeted Therapies in Breast CancerK23CA127469 · NCI · VANDERBILT UNIVERSITY · PI MAYER, INGRID A · 2009 to 2013
$820kNCI NIH HHS K23 CA127469NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA070856NCI NIH HHS R01 CA105436
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultCisplatinDNA DamageDrug-Related Side Effects and Adverse ReactionsEverolimusFemaleHigh-Throughput Nucleotide SequencingHumansKi-67 AntigenLymphocytes, Tumor-InfiltratingMiddle AgedMutationNeoplasm StagingPaclitaxelReceptors, AndrogenTreatment OutcomeCisplatinEverolimusKi-67 AntigenPaclitaxelReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.